PITAVASTATIN vs SIMVASTATIN

Compare PITAVASTATIN (Pitavastatin Calcium) and SIMVASTATIN (SIMVASTATIN) — clinical data, side effects, and patient experiences.

PITAVASTATIN

Pitavastatin Calcium · Other

How it works

12.1 Mechanism of Action Pitavastatin is an inhibitor of 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase, the enzyme that catalyzes the conversion of HMG-CoA to mevalonat...

Approved for

See full prescribing information

OralTablet

SIMVASTATIN

SIMVASTATIN, Zocor · Statin

How it works

12.1 Mechanism of Action Simvastatin is a prodrug and is hydrolyzed to its active β-hydroxyacid form, simvastatin acid, after administration. Simvastatin acid and its metabolites a...

Approved for

1 INDICATIONS AND USAGE Simvastatin tablets USP are indicated: To reduce the risk of total mortality by reducing risk of coronary heart disease death

non-fatal myocardial infarction and stroke

and the need for coronary and non-coronary revascularization procedures in adults with established coronary heart disease

cerebrovascular disease

OralTablet

Quick Comparison

PITAVASTATINSIMVASTATIN

Drug Class

Other

Statin

Route

Oral

Half-Life

—

FDA Approved

—

Side Effect Frequency Comparison

Estimated frequency (%) based on clinical trial data

Side Effects

PITAVASTATIN

Muscle Pain

>10%

Diarrhea

1-10%

Fatigue

1-10%

Nausea

1-10%

Headache

1-10%

Joint Pain

1-10%

Dizziness

1-10%

Shortness of Breath

1-10%

SIMVASTATIN

Fatigue

1-10%

Nausea

1-10%

Shortness of Breath

1-10%

Diarrhea

1-10%

Drug Not Working

1-10%

Dizziness

1-10%

Weakness

1-10%

Falls

1-10%

FDA Warnings

PITAVASTATIN

5 WARNINGS AND PRECAUTIONS • Myopathy and Rhabdomyolysis: Risk factors include age 65 or greater, uncontrolled hypothyroidism, renal impairment, concomitant use with certain other drugs, and higher pitavastatin tablets dosage
Temporarily discontinue pitavastatin tablets in patients experiencing an acute or serious condition at high risk of developing renal failure secondary to rhabdomyolysis
Inform patients of the risk of myopathy and rhabdomyolysis when starting or increasing the pitavastatin tablets dosage
Rare reports of fatal and non-fatal hepatic failure have occurred

SIMVASTATIN

5 WARNINGS AND PRECAUTIONS Myopathy and Rhabdomyolysis: Risk factors include age 65 years or greater, uncontrolled hypothyroidism, renal impairment, concomitant use with certain other drugs, and higher simvastatin dosage
Chinese patients may be at higher risk for myopathy
Temporarily discontinue simvastatin in patients experiencing an acute or serious condition at high risk of developing renal failure secondary to rhabdomyolysis
Inform patients of the risk of myopathy and rhabdomyolysis when starting or increasing simvastatin dosage

Clinical Trial Data

No head-to-head clinical studies found for PITAVASTATIN vs SIMVASTATIN.

PITAVASTATIN vs SIMVASTATIN: What You Should Know

Key Differences

PITAVASTATIN is a Other, while SIMVASTATIN belongs to the Statin class. This means they work through different pharmacological mechanisms, which may influence both efficacy and side effect profiles.

Safety Considerations

PITAVASTATIN carries 4 FDA warnings. SIMVASTATIN carries 4 FDA warnings. Patients should discuss all warnings and contraindications with their healthcare provider before starting or switching medications..

This comparison is for informational purposes only. Always consult a qualified healthcare professional before making medication decisions.

Related Comparisons

EZETIMIBE AND SIMVASTATIN vs SIMVASTATIN→LOVASTATIN vs SIMVASTATIN→OCTREOTIDE vs SIMVASTATIN→Atorvastatin vs SIMVASTATIN→Atorvastatin vs PITAVASTATIN→Rosuvastatin vs SIMVASTATIN→

Loading comparison data...

PITAVASTATIN vs SIMVASTATIN

Compare PITAVASTATIN (Pitavastatin Calcium) and SIMVASTATIN (SIMVASTATIN) — clinical data, side effects, and patient experiences.

PITAVASTATIN

Pitavastatin Calcium · Other

How it works

12.1 Mechanism of Action Pitavastatin is an inhibitor of 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase, the enzyme that catalyzes the conversion of HMG-CoA to mevalonat...

Approved for

See full prescribing information

OralTablet

SIMVASTATIN

SIMVASTATIN, Zocor · Statin

How it works

12.1 Mechanism of Action Simvastatin is a prodrug and is hydrolyzed to its active β-hydroxyacid form, simvastatin acid, after administration. Simvastatin acid and its metabolites a...

Approved for

1 INDICATIONS AND USAGE Simvastatin tablets USP are indicated: To reduce the risk of total mortality by reducing risk of coronary heart disease death

non-fatal myocardial infarction and stroke

and the need for coronary and non-coronary revascularization procedures in adults with established coronary heart disease

cerebrovascular disease

OralTablet

Quick Comparison

PITAVASTATINSIMVASTATIN

Drug Class

Other

Statin

Route

Oral

Half-Life

—

FDA Approved

—

Side Effect Frequency Comparison

Estimated frequency (%) based on clinical trial data

Side Effects

PITAVASTATIN

Muscle Pain

>10%

Diarrhea

1-10%

Fatigue

1-10%

Nausea

1-10%

Headache

1-10%

Joint Pain

1-10%

Dizziness

1-10%

Shortness of Breath

1-10%

SIMVASTATIN

Fatigue

1-10%

Nausea

1-10%

Shortness of Breath

1-10%

Diarrhea

1-10%

Drug Not Working

1-10%

Dizziness

1-10%

Weakness

1-10%

Falls

1-10%

FDA Warnings

PITAVASTATIN

5 WARNINGS AND PRECAUTIONS • Myopathy and Rhabdomyolysis: Risk factors include age 65 or greater, uncontrolled hypothyroidism, renal impairment, concomitant use with certain other drugs, and higher pitavastatin tablets dosage
Temporarily discontinue pitavastatin tablets in patients experiencing an acute or serious condition at high risk of developing renal failure secondary to rhabdomyolysis
Inform patients of the risk of myopathy and rhabdomyolysis when starting or increasing the pitavastatin tablets dosage
Rare reports of fatal and non-fatal hepatic failure have occurred

SIMVASTATIN

5 WARNINGS AND PRECAUTIONS Myopathy and Rhabdomyolysis: Risk factors include age 65 years or greater, uncontrolled hypothyroidism, renal impairment, concomitant use with certain other drugs, and higher simvastatin dosage
Chinese patients may be at higher risk for myopathy
Temporarily discontinue simvastatin in patients experiencing an acute or serious condition at high risk of developing renal failure secondary to rhabdomyolysis
Inform patients of the risk of myopathy and rhabdomyolysis when starting or increasing simvastatin dosage

Clinical Trial Data

No head-to-head clinical studies found for PITAVASTATIN vs SIMVASTATIN.

PITAVASTATIN vs SIMVASTATIN: What You Should Know

Key Differences

PITAVASTATIN is a Other, while SIMVASTATIN belongs to the Statin class. This means they work through different pharmacological mechanisms, which may influence both efficacy and side effect profiles.

Safety Considerations

This comparison is for informational purposes only. Always consult a qualified healthcare professional before making medication decisions.